Phase 2 trial of experimental oral treatment enrolling fragile X males
Mirum Pharmaceuticals has launched a proof-of-concept Phase 2 clinical trial to test its experimental oral treatment MRM-3379 in boys and men with fragile X syndrome. The therapy, acquired by the company last year, is designed to restore the disrupted brain signaling that characterizes fragile X syndrome, which…
